DNA topoisomerase I
Topoisomerase 1 Dmel_CG6146 is the Drosophila melanogaster ortholog of human DNA topoisomerase I (TOP1), encoded by CG6146. topoisomerase I resolves the topological strain that accumulates ahead of replication forks and transcribing polymerases: it cleaves one strand of the duplex, forming a transient covalent intermediate — the TOP1 cleavage complex (TOP1cc), in which an active-site tyrosine is linked to the 3′ end of the nick — allows the DNA to rotate about the intact strand, and then reseals it.
Topoisomerase 1 Dmel_CG6146 is the Drosophila melanogaster ortholog of human DNA topoisomerase I (TOP1), encoded by CG6146. topoisomerase I resolves the topological strain that accumulates ahead of replication forks and transcribing polymerases: it cleaves one strand of the duplex, forming a transient covalent intermediate — the TOP1 cleavage complex (TOP1cc), in which an active-site tyrosine is linked to the 3′ end of the nick — allows the DNA to rotate about the intact strand, and then reseals it. Unlike type II enzymes it needs no ATP, since the energy of the broken phosphodiester bond is stored in the protein–DNA link and recovered on religation. The reaction is essential in both directions of gene expression, and without it transcription generates positive supercoils ahead and negative supercoils behind that stall the polymerase and promote R-loop formation.
The enzyme is one of the most validated antitumor drug targets, for a reason that lies in its intermediate rather than its function. camptothecin-class inhibitors do not block catalysis; they bind at the enzyme–DNA interface and prevent religation, converting a normal transient intermediate into a persistent protein-linked single-strand break. Double-strand breaks arise secondarily, when a replication fork or transcription complex collides with the trapped complex or during its processing — which makes the drugs S-phase selective and makes exposure time, rather than peak concentration, the determinant of cell kill. Cells defend themselves by removing the adduct: tyrosyl-DNA phosphodiesterase 1 (TDP1) hydrolyzes the tyrosyl–DNA bond, and its loss sensitizes cells to these agents, while hereditary TDP1 deficiency causes a neurodegenerative ataxia, showing that trapped complexes accumulate in non-dividing neurons too.
The Drosophila protein is highly conserved with its human counterpart and has served as a tractable genetic and biochemical model for TOP1 function, inhibitor sensitivity and the DNA damage response — a role that depends on that conservation, since the trapping mechanism and its repair are shared across the eukaryotes.
Where the papers sit
12 papers from the last 6 months study DNA topoisomerase I directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 1 observational · 9 preclinical · 2 unclassified
Themes 3 themes · 1 new direction
-
Next-Generation TOP1 Therapies
TOP1 therapy is moving beyond conventional camptothecins toward dual inhibitors, degraders, antibody-drug conjugates and supramolecular delivery systems. PARP1 inhibition, CDK7 blockade and hydrophobic tagging are used to increase tumor sensitivity or convert camptothecin into a degrader. Bioorthogonal release and phospholipid nanotubes seek better tumor delivery, while linker hydrolysis and lactone-ring opening complicate drug-to-antibody ratio measurement. The direction is combination and formulation optimization, but benefit remains largely preclinical.
6 papers · 50%
-
Breast Cancer Therapeutics
TROP2 antibody-drug conjugates are being evaluated alongside mechanistic work linking inflammation to breast cancer progression. Safety management, particularly interstitial lung disease, is a prominent concern for anti-TROP2 ADCs. Thrombin-PAR1 signaling connects inflammatory cues to Topoisomerase 1 activity, suggesting a route to understand tumor behavior rather than a validated treatment. Pharmacogenomics and AI may support risk stratification, but no common therapeutic direction is established.
2 papers · 16.7%
-
Others — Cancer Drugs and Jaw Surgery
Camptothecin and selenium–matrine hybrids are being explored as TOP1-targeted anticancer agents, with potency and apoptosis as recurring endpoints. Hydroxycamptothecin design uses molecular dynamics, while A10 formulation work targets oral bioavailability and cGAS-STING/ICD activation in bladder cancer. A separate mandibular AOT report concerns combined treatment and bone healing, not TOP1 biology. No single translational direction unites the cluster.
4 papers · 33.3%
Thrombin–PAR1 signaling positions DNA topoisomerase I as an inflammatory signaling effector rather than only a DNA-damage target
The thrombin–PAR1 signaling model in triple-negative breast cancer found that thrombin increased Top1 activity without changing its expression, thereby amplifying NF-κB-dependent cytokine production through Par-4 suppression 42219057May. This departs from the set’s predominant use of DNA topoisomerase I as a pharmacological target or cytotoxic payload that produces DNA damage: Top1 instead functions downstream of coagulation signaling to connect the tumor microenvironment with inflammatory transcription. As a result, Top1 activity becomes a potential mechanistic link—and intervention point—for thrombin-driven inflammation and breast-cancer progression, not merely a means of killing tumor cells.
Papers
The 12 papers from the last 6 months that study DNA topoisomerase I directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Next-Generation TOP1 Therapies (6)
- Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science advances · 30 Sept 2026 PMID 42814835
- Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
- Surface-Confinement Effect Enables Bioorthogonal Drug Release in Tumors. Journal of the American Chemical Society · 17 Jul 2026 PMID 42468144
- A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
- Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly. Journal of the American Chemical Society · 30 Jun 2026 PMID 42378337
- A Case Study on the Impact of Thermal Hydrolysis and Lactone Ring Opening of Linker-Payload on Drug-to-Antibody Ratio Determination in a Topoisomerase I Inhibitor-Based ADC. Bioconjugate chemistry · 4 Jun 2026 PMID 42237689
Breast Cancer Therapeutics (2)
- Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
- Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression. Cancer letters · 31 May 2026 PMID 42219057
Others — Cancer Drugs and Jaw Surgery (4)
- Management of mandibular AOT: outcomes following combined treatment protocol. BMJ case reports · 24 Sept 2026 PMID 42785786
- Discovery of novel hydroxycamptothecin derivatives as potent Topo I inhibitors for antitumor guided by molecular dynamics. European journal of medicinal chemistry · 24 Jul 2026 PMID 42497470
- Soluplus®-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy. International journal of pharmaceutics · 12 Jul 2026 PMID 42437626
- Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry · 4 Jul 2026 PMID 42401165
By study type
Observational studies and case reports (1)
- Management of mandibular AOT: outcomes following combined treatment protocol. BMJ case reports · 24 Sept 2026 PMID 42785786
Preclinical: animal, cell and lab studies (9)
- Sensitizing tumor response to topoisomerase I antibody-drug conjugate by selective CDK7 inhibition. Science advances · 30 Sept 2026 PMID 42814835
- Molecular Construction and Anti-Bladder Cancer Study of Novel TOP1/PARP1 Dual-Target Inhibitors. Journal of medicinal chemistry · 27 Jul 2026 PMID 42504569
- Discovery of novel hydroxycamptothecin derivatives as potent Topo I inhibitors for antitumor guided by molecular dynamics. European journal of medicinal chemistry · 24 Jul 2026 PMID 42497470
- Surface-Confinement Effect Enables Bioorthogonal Drug Release in Tumors. Journal of the American Chemical Society · 17 Jul 2026 PMID 42468144
- A phospholipid Camptothecin-Niraparib conjugate self-assembled into supramolecular nanotubes for combination cancer therapy. Journal of controlled release : official journal of the Controlled Release Society · 15 Jul 2026 PMID 42456976
- Soluplus®-based solid dispersion enhances oral bioavailability of A10: a cGAS-STING and ICD activator for bladder cancer therapy. International journal of pharmaceutics · 12 Jul 2026 PMID 42437626
- Design, synthesis, and biological evaluation of novel selenium-matrine hybrid compounds as topo I -targeted anticancer agents. Bioorganic chemistry · 4 Jul 2026 PMID 42401165
- A Case Study on the Impact of Thermal Hydrolysis and Lactone Ring Opening of Linker-Payload on Drug-to-Antibody Ratio Determination in a Topoisomerase I Inhibitor-Based ADC. Bioconjugate chemistry · 4 Jun 2026 PMID 42237689
- Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression. Cancer letters · 31 May 2026 PMID 42219057
Unclassified: not yet indexed with MeSH (2)
- Safety management of anti TROP2 ADCs in patients with breast cancer. Current opinion in oncology · 18 Sept 2026 PMID 42757501
- Reprogramming Aromatic Camptothecins into TOP1 Degraders via Synergistic Hydrophobic Tagging and Supramolecular Assembly. Journal of the American Chemical Society · 30 Jun 2026 PMID 42378337
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-26 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.